151 Investigating BMP signaling as a therapeutic target in advanced melanoma
Melanoma is the leading cause of skin cancer death in the United States, with a 5-year survival rate of 20% for patients with advanced disease. The development of targeted therapies and immunotherapy has helped improve survival for some patients, but many others still face significant therapeutic challenges, including resistance to therapy and relapse of their disease. Furthermore, our understanding of the steps involved in melanoma initiation and progression is incomplete. We are interested in uncovering factors involved in melanoma initiation and progression with a focus on identifying those key factors that have therapeutic potential.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: A.K. Gramann, A.M. Venkatesan, C.J. Ceol Tags: Carcinogenesis and Cancer Genetics Source Type: research
More News: Cancer | Cancer & Oncology | Dermatology | Genetics | Immunotherapy | Melanoma | Skin | Skin Cancer | USA Health